M L Hensley

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
  2. ncbi request reprint Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
    Gynecol Oncol 89:440-6. 2003
  3. ncbi request reprint Economic outcomes of breast cancer survivorship: CALGB study 79804
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 91:153-61. 2005
  4. ncbi request reprint A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
  5. doi request reprint Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors
    Roisin O'Cearbhaill
    Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:424-9. 2010
  6. pmc Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival
    Sewit Teckie
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Radiat Oncol 8:36. 2013
  7. doi request reprint Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:1555-61. 2013
  8. pmc Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    Cancer 118:2403-10. 2012
  9. doi request reprint A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
  10. doi request reprint Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Best Pract Res Clin Obstet Gynaecol 25:773-82. 2011

Detail Information

Publications62

  1. ncbi request reprint Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS...
  2. ncbi request reprint Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
    Gynecol Oncol 89:440-6. 2003
    ..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
  3. ncbi request reprint Economic outcomes of breast cancer survivorship: CALGB study 79804
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 91:153-61. 2005
    ..Over 80% of women diagnosed with breast cancer will be survivors. We sought to determine the economic consequences of surviving breast cancer...
  4. ncbi request reprint A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
    ..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
  5. doi request reprint Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors
    Roisin O'Cearbhaill
    Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:424-9. 2010
    ..Aromatase inhibitors are sometimes used in the treatment of selected patients with uterine leiomyosarcoma (LMS), but there are few data assessing the efficacy of aromatase inhibitors in this setting...
  6. pmc Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival
    Sewit Teckie
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Radiat Oncol 8:36. 2013
    ..Brain metastases (BM) and leptomeningeal disease (LMD) are uncommon in epithelial ovarian cancer (EOC). We investigate the outcomes of modern radiation therapy (RT) as a primary treatment modality in patients with EOC BM and LMD...
  7. doi request reprint Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:1555-61. 2013
    ..The objective of the current study was to determine the 2-year and 3-year progression-free survival (PFS) among a prospective cohort of women who received adjuvant gemcitabine plus docetaxel followed by doxorubicin...
  8. pmc Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    Cancer 118:2403-10. 2012
    ..In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer...
  9. doi request reprint A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
    ..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
  10. doi request reprint Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Best Pract Res Clin Obstet Gynaecol 25:773-82. 2011
    ..Uterine carcinosarcomas also carry a high risk of recurrence. Adjuvant chemotherapy is a standard approach for completely resected and metastatic carcinosarcoma. Active agents include carboplatin, cisplatin, ifosfamide and paclitaxel...
  11. ncbi request reprint Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013
    M L Hensley
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 18:1301-8. 2000
    ..The purpose of this study was to identify predictors for the development of severe neuropsychiatric toxicity in CML patients receiving rIFNalpha2b-based therapy...
  12. pmc Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 115:460-5. 2009
    ..We also aimed to characterize the toxicity of sunitinib and to estimate time-to-progression...
  13. ncbi request reprint Epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 3:131-41. 2002
    ..Novel approaches to managing minimal residual disease are being tested in hopes of decreasing the number of patients who relapse after achieving complete clinical remission...
  14. ncbi request reprint The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients
    M L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Gynecol Oncol 82:464-9. 2001
    ....
  15. pmc Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 109:323-8. 2008
    ..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
  16. ncbi request reprint Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer
    M L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Gynecol Oncol 81:485-9. 2001
    ..We sought to identify pretreatment risk factors that could identify patients at increased risk for requiring RBC transfusion during first-line treatment for ovarian cancer...
  17. doi request reprint Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer
    M M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 129:38-41. 2013
    ..To determine whether the frequency of cases diagnosed with stage IIIC endometrial cancer is affected by the incorporation of a modified surgical lymph node assessment...
  18. ncbi request reprint A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer
    A L Leiser
    Division of Solid Tumor Oncology, Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Gynecol Cancer 17:379-86. 2007
    ....
  19. ncbi request reprint Paclitaxel-based chemotherapy in carcinoma of the fallopian tube
    M L Gemignani
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Gynecol Oncol 80:16-20. 2001
    ..CONCLUSION: Optimally cytoreduced patients with primary fallopian tube carcinoma treated with a paclitaxel-based chemotherapy regimen have an excellent possibility of survival...
  20. doi request reprint Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes
    F Khoury-Collado
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY, NY 10065, USA
    Gynecol Oncol 122:251-4. 2011
    ..non-sentinel nodes in patients who had lymphatic mapping for endometrial cancer and to determine the contribution of metastases detected on ultrastaging to the overall nodal metastasis rate...
  21. ncbi request reprint A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission
    M Juretzka
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur J Gynaecol Oncol 29:568-72. 2008
    ..To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR)...
  22. doi request reprint A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care
    N R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:399-403. 2010
    ..Our objective was to develop a clinically useful nomogram in the hope of providing a more individualized and accurate estimation of overall survival (OS) following primary therapy...
  23. doi request reprint A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma
    Vicky Makker
    Memorial Sloan Kettering Cancer Center Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA
    Gynecol Oncol 111:249-54. 2008
    ..To determine the progression-free survival (PFS) and overall survival (OS) in a cohort of patients who received either platinum-based chemotherapy with or without radiation therapy (pelvic or WAI), or RT alone...
  24. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  25. ncbi request reprint Identification of prognostic factors in advanced epithelial ovarian carcinoma
    D S Chi
    Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 82:532-7. 2001
    ....
  26. ncbi request reprint CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  27. ncbi request reprint Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  28. ncbi request reprint Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study
    Mika A Sovak
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:451-7. 2006
    ..To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection...
  29. ncbi request reprint Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease
    M H Einstein
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Gynecol Cancer 18:1065-70. 2008
    ..Patients who undergo completion surgery with restaging and are not upstaged appear to have a good prognosis. Surgical staging is valuable for prognosis and may alter postoperative treatments...
  30. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  31. doi request reprint What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 111:46-8. 2008
    ..To describe the incidence of isolated paraaortic nodal recurrences in patients with a final diagnosis of grade 1 endometrial carcinoma initially treated with surgery...
  32. doi request reprint The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes
    Nadeem R Abu-Rustum
    Memorial Sloan Kettering Cancer Centerm, 1275 York Ave, NY, NY 10065, USA
    Gynecol Oncol 115:236-8. 2009
    ..To describe the incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes...
  33. doi request reprint Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  34. doi request reprint Cognitive functions in long-term survivors of ovarian cancer
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 119:366-9. 2010
    ..This cross-sectional study assessed neuropsychological functions in long-term survivors of ovarian cancer who were either in complete remission or with evidence of recurrent disease...
  35. doi request reprint Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Oncol 22:356-61. 2010
    ..The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed...
  36. doi request reprint Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 112:563-7. 2009
    ..We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population...
  37. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  38. pmc Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 109:329-34. 2008
    ..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
  39. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  40. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
  41. ncbi request reprint Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
    ..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
  42. ncbi request reprint Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer
    Monica Prasad
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:223-8. 2004
    ..We report overall costs and treatment outcomes associated with topotecan or gemcitabine administration in platinum- and paclitaxel-resistant EOC patients...
  43. ncbi request reprint Early detection and prognosis of ovarian cancer using serum YKL-40
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3330-9. 2004
    ..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
  44. ncbi request reprint Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up
    Noah D Kauff
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:314-20. 2005
    ..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
  45. ncbi request reprint Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1096, New York, NY 10021, USA
    Gynecol Oncol 99:320-6. 2005
    ....
  46. ncbi request reprint Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 102:270-7. 2006
    ....
  47. ncbi request reprint Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
    Don S Dizon
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 84:378-82. 2002
    ..One case is presented in which a heavily pretreated patient suffered a severe anaphylactic reaction, which was refractory to standard resuscitative measures and resulted in her death...
  48. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  49. ncbi request reprint Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  50. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  51. ncbi request reprint Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
    Don S Dizon
    Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 20:1238-47. 2002
    ..We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC...
  52. ncbi request reprint Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Tim P Hughes
    Institute of Medical and Veterinary Science, Adelaide, SA, Australia
    N Engl J Med 349:1423-32. 2003
    ..We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission...
  53. ncbi request reprint Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study
    M A Sovak
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Gynecol Cancer 17:197-203. 2007
    ..3 months (95% CI, 4.6-7.4), with a median overall survival of 13.2 months (95% CI, 11.7-18.2). We conclude that TC is an active and tolerable regimen in the treatment of patients with advanced or recurrent endometrial cancer...
  54. pmc Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems
    Oliver Zivanovic
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:2066-72. 2009
    ..We aimed to determine whether the American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurate in predicting progression-free survival (PFS) and overall survival (OS)...
  55. doi request reprint Optimal management of uterine leiomyosarcoma
    Roisin O'Cearbhaill
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Expert Rev Anticancer Ther 10:153-69. 2010
    ..First-line treatment options include gemcitabine-docetaxel or doxorubicin with or without ifosfamide. Novel targeted therapies are under investigation in an attempt to devise more effective treatment strategies...
  56. ncbi request reprint Rare uterine cancers
    Sheetal Acharya
    UP Hematology Associates, Marquette, MI, USA
    Lancet Oncol 6:961-71. 2005
    ..This review summarises the epidemiology, clinical characteristics, and prognoses of the less common malignant diseases of the uterus, and presents the information available to guide the clinician about treatment options...
  57. ncbi request reprint Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study
    Elizabeth A Hahn
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, 1001 University Pl, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 21:2138-46. 2003
    ..Quality of life (QOL) outcomes in patients with chronic myeloid leukemia (CML) were evaluated in an international phase III study...
  58. doi request reprint American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 27:127-45. 2009
    ..To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer...
  59. ncbi request reprint 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology
    Lynn M Schuchter
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 20:2895-903. 2002
  60. ncbi request reprint Cancer screening: how good is good enough?
    Martee L Hensley
    J Clin Oncol 22:4037-9. 2004
  61. ncbi request reprint The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions
    Margrit M Juretzka
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:670-4. 2007
    ..The objective of this study was to report the surgical findings and management of patients who underwent VATS in an update of our experience...
  62. ncbi request reprint Amifostine and chemoradiation therapy: ASCO responds
    Lynn Schuchter
    University of Pennsylvania, PA, USA
    Lancet Oncol 4:593. 2003